Texas Children´s Hospital
Welcome,         Profile    Billing    Logout  
 4 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Allen, Carl E
NCT03213691: Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Active, not recruiting
2
21
US
Laboratory Biomarker Analysis, Selumetinib, ARRY-142886, AZD 6244, AZD-6244, AZD6244, MEK Inhibitor AZD6244, Selumetinib Sulfate, AZD-6244 Hydrogen Sulfate, AZD6244 Hydrogen Sulfate, AZD6244 Hydrogen Sulphate, Koselugo, Selumetinib Sulphate
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm
06/21
09/25
NCT01858922: Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A

Completed
2
40
US
ABVE-PC, Doxorubicin (A), Bleomycin (B), Vincristine (V), Etoposide (E), Prednisone (P), Cyclophosphamide (C), DECA, Dexamethasone (D), Cytarabine (A), Cisplatin (C)
Baylor College of Medicine
Hodgkin Disease
08/19
08/19
NACHO COBI, NCT04079179: Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

Recruiting
2
90
US
Cobimetinib, COTELLIC, RO5514041
Carl Allen, Baylor College of Medicine, North American Consortium for Histiocytosis, Genentech, Inc.
Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma, Erdheim-Chester Disease, Rosai Dorfman Disease, Neuro-Degenerative Disease, Histiocytic Sarcoma, Histiocytic Disorders, Malignant
12/24
12/29
NCT06730126: Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients

Recruiting
2
15
US
Soquelitinib
National Institute of Allergy and Infectious Diseases (NIAID)
Autoimmune Lymphoproliferative Syndrome
03/26
12/26
NCT05287295: A Study With DAY101 as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Not yet recruiting
2
28
NA
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, FDG-Positron Emission Tomography and Computed Tomography Scan, FDG PET/CT, Tovorafenib, BIIB-024, DAY 101, DAY-101, DAY101, MLN-2480, MLN2480, pan-RAF Kinase Inhibitor DAY101, TAK-580, TAK580
Children's Oncology Group
Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
05/25
05/25
MAS NLRC4-GOF, NCT04641442: Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations

Active, not recruiting
2
17
Europe, Japan, US, RoW
MAS825, Placebo
Novartis Pharmaceuticals
NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations
11/25
02/29
Canna, Scott
MAS NLRC4-GOF, NCT04641442: Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations

Active, not recruiting
2
17
Europe, Japan, US, RoW
MAS825, Placebo
Novartis Pharmaceuticals
NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations
11/25
02/29
NCT02418442: Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry

Recruiting
N/A
20000
Europe, Canada, US, RoW
Duke University, Childhood Arthritis and Rheumatology Research Alliance
Rheumatic Joint Disease
06/28
12/28

Download Options